The anticancer agent sulforaphane (SFN) acts via multiple mechanisms to modulate gene expression, including the induction of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-dependent signaling and the inhibition of histone deacetylase activity. Transcriptomics studies were performed in SFN-treated human colon cancer cells and in nontransformed colonic epithelial cells in order to pursue new mechanistic leads. Methods and results: RNA-sequencing corroborated the expected changes in cancer-related pathways after SFN treatment. In addition to NAD(P)H quinone dehydrogenase 1 (NQO1) and other well-known Nrf2-dependent targets, SFN strongly induced the expression of Loc344887. This noncoding RNA was confirmed as a novel functional pseudogene for NmrA-like redox sensor 1, and was given the name NmrA-like redox sensor 2 pseudogene (NMRAL2P). Chromatin immunoprecipitation experiments corroborated the presence of Nrf2 interactions on the NM-RAL2P genomic region, and interestingly, NMRAL2P also served as a coregulator of NQO1 in human colon cancer cells. Silencing of NMRAL2P via CRISPR/Cas9 genome-editing protected against SFN-mediated inhibition of cancer cell growth, colony formation, and migration. Conclusion: NMRAL2P is the first functional pseudogene to be identified both as a direct transcriptional target of Nrf2, and as a downstream regulator of Nrf2-dependent NQO1 induction. Further studies are warranted on NMRAL2P-Nrf2 crosstalk and the associated mechanisms of gene regulation.
Introduction
Sulforaphane (SFN) is a dietary agent that exerts anticancer effects against various malignancies, including colorectal cancer [1, 2] . Chemopreventive outcomes of SFN have been attributed to multiple mechanisms [3] [4] [5] [6] [7] [8] [9] [10] . SFN regulates antioxidant activity and the detoxification of carcinogens through induction of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway [11, 12] . Under normal conditions, Nrf2 is sequestered in the cytosol by protein partner Kelch-like ECH-associated protein 1 (Keap1). Upon treatment with SFN, Nrf2 dissociates from Keap1, translocates to the nucleus, and dimerizes with small musculoaponeurotic fibrosarcoma (MAF) proteins on the antioxidant response element (ARE) sequences of target genes [10, 13] . Target genes activated by Nrf2 include NAD(P)H quinone dehydrogenase 1 (NQO1), heme oxygenase 1 (HMOX1), and various glutathione S-transferases. The response of these genes is influenced by nuclear/cytoplasmic trafficking of Nrf2, and by posttranslational modifications that affect its interactions with small MAF proteins, chromatin remodeling factors, histone deacetylase (HDAC) enzymes, and other transcriptional regulators [14] [15] [16] [17] [18] .
Among the epigenetic mechanisms implicated in human colon and prostate cancer cells, SFN has been shown to act via HDAC inhibition/turnover and changes in DNA methylation [19] [20] [21] [22] . Acetylation of histone and nonhistone proteins was linked to derepression of tumor suppressor genes and the activation of apoptotic and G 2 /M cell arrest pathways, most notably in cancer cells as compared with the corresponding nontransformed cell lines [21] [22] [23] [24] .
Dietary isothiocyanates also alter the expression of various noncoding RNAs (ncRNAs), including microRNAs (miRNAs) [25] such as mir-155, mir-23b, and mir-27b in colonic epithelial cells [26] ; mir-155 in macrophages [27] ; miR-200c in bladder cancer cells [28] ; mir-21 in glioblastoma [29] ; and let-7 family members in pancreatic ductal adenocarcinoma cells [30] . Other ncRNAs, such as long noncoding RNAs (lncRNAs) and pseudogenes, also have been identified with roles in gene regulation, genome stability, cancer cell survival, and drug resistance [31] [32] [33] [34] [35] [36] [37] . There is a general lack of information on how these various ncRNAs might be impacted by diet and lifestyle factors.
While performing transcriptomics studies in SFN-treated colon cancer cells and in nontransformed colonic epithelial cells, we identified an ncRNA, Loc344887, that was directly regulated by Nrf2, and that served as a coactivator for NQO1. Localized on chromosome 3q27.2 and sharing 62% homology with the protein-coding gene NmrA-like redox sensor 1 (NMRAL1) on chromosome 16p13.3, the novel functional pseudogene was assigned the name NmrA-like redox sensor 2 (NMRAL2P), and was pursued in mechanistic studies of cell viability, colony formation, and cell migration.
Materials and methods

Cell culture and treatments
Cell lines were obtained from ATCC and grown at 37ЊC in 5% CO 2 with 1% penicillin/streptomycin. Human colon cancer cell lines HCT116 and HT29 were maintained in McCoy's 5A media (Invitrogen) supplemented with 10% heat inactivated fetal bovine serum, whereas Caco2 cells and CCD841 nontransformed colonic epithelial cells were maintained in EMEM supplemented with 20% fetal bovine serum. Treatments were performed when cells were ß70% confluent. Unless indicated otherwise, cells were incubated with 15 M SFN or with the corresponding volume of DMSO vehicle. Allyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 9-methylsulfinylnonyl isothiocyanate, Oltipraz, tertbutylhydroquinone (TBHQ), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), valproic acid, and sodium butyrate were used in some experiments. Concentrations were based on predetermined IC 50 values and prior reports [21, 22, 38] .
RNA isolation and sequencing
RNA was isolated using the miRNeasy kit (Qiagen), according to the manufacturer's protocol. For RNA-seq, RNA was isolated with Trizol (Life Technologies) and was purified and processed as reported [39] . In some experiments, the PARIS kit (ThermoFisher) was used to isolate nuclear and cytosolic RNA. Enrichment of nuclear RNA was confirmed by reference to metastasis associated lung adenocarcinoma transcript 1. For a comprehensive list of the primers used, see Supporting Information Table 1. RNA-seq data quality was examined using Fastqc, and low quality reads (>50% bases with Q < 30) were filtered out. Bowtie2 with default parameters was used to map reads to hg19 reference genome. Uniquely mapped genes were used to calculate the RPKM for each gene, and DESeq2 (R package) was used to identify significant differentially expressed genes (DEGs) with a threshold of fdr < 0.05 and fold change >4. GOstats (R package) was used to perform KEGG pathway enrichment analysis, with a threshold of p < 0.05. The Cancer Genome Atlas (TCGA) data for NMRAL2P were downloaded from the colon adenocarcinoma dataset. Nrf2 target genes were selected from the ChIP-seq data of Chorley et al. [40] , whereas Wnt signaling genes were identified from the gene list generated by Yu et al. [41] .
Quantitative PCR
SuperScript III First-Strand Synthesis Master Mix (Invitrogen) was used on 1 g of RNA to synthesize cDNA. Quantitative PCR was performed using SYBR Green I dye (Roche), cDNA, and gene-specific primers. Assays were run in a Light Cycler 96 or 480 (Roche) and normalized to glyceraldehyde-3-phosphate dehydrogenase using the 2 −⌬⌬CT method. Each experiment was repeated at least twice, and data were normalized to vehicle controls.
CRISPR-Cas9 genome editing
A small guide RNA (sgRNA NMRAL2P [upstream1], Supporting Information Table 1 ), specific to the promoter region of NMRAL2P, was designed by clustered regularly interspaced short palindromic repeats (CRISPR) Design (crispr.mit.edu). Restriction cloning was used to insert the sgRNA into plasmid pSPCas9(BB)-2A-GFP (PX458), kindly provided by Dr. Feng Zhang (Addgene plasmid #48138) [42] . In brief, oligos were annealed by temperature ramp-down, phosphorylated, and ligated into the BbsI site of PX458 which contained sgRNA expression, Cas9 protein, and eGFP selection marker. PX458 plasmid (2.5 g) was transfected into cells in a six-well dish for 24 h. Green fluorescing cells were sorted individually into 96-well plates on a BD Biosciences FACSFusion Cell Sorter. Primers flanking exon 1 of NMRAL2P (see Supporting Information Table 1 ) were used to screen genomic DNA of individual colonies, and PCR products were confirmed by sequencing.
siRNA transfection
Gene specific siRNAs (Sigma-Aldrich) or a Universal Control were transfected into cells using RNAiMax transfection reagent (Invitrogen), according to the manufacturer's protocol. Unless stated otherwise, siRNA incubations were for 24-48 h. For siRNA primer sequences, see Supporting Information Table 1 .
MTT assays
Each treatment was performed in triplicate on NMRAL2P knockout cells, or the corresponding vector controls, plated at 1 × 10 4 cells per well. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added at 500 g/mL and incubated at 37ЊC for 2 h. Resulting formazan dye was solubilized in DMSO and absorbance was measured at 562 nm (OD562).
Soft agar colony formation assays
Six-well plates were precoated with 0.6% agarose Type III-A (Sigma). Cells were mixed with 0.4% top agar and added to precoated plates at 3 × 10 4 cells/well. After solidifying, 2 mL of liquid media containing SFN or DMSO was added to each well. Each treatment was performed in triplicate. Cells were incubated at 37ЊC for 2 weeks, and stained with 0.5% crystal violet in 6% formaldehyde. Two independent experiments were performed as biological replicates.
Transwell assays
To the upper chamber of a transwell insert was added 3 × 10 4 cells in serum-free media (Costar #3422), and serumcontaining media without cells was added to the bottom chamber. After 24 h, inserts were fixed with 6% formaldehyde, the top of the membrane was swabbed, and then stained with 0.2% crystal violet. Membranes were washed and mounted onto glass slides. The number of cells that migrated through the insert was counted for ten 10X fields per treatment, for three wells per treatment. The experiment was repeated three times.
Immunoblotting
Cells were suspended in IP lysis buffer and lysed by freezethawing. Immunoblotting used the methodology described previously [21, 22] , with primary antibodies to Keap1 (Cell Signaling #4617), Nrf2 (Cell Signaling #12721), NQO1(Cell Signaling #3187), and ␤-Actin (Sigma #A1978).
Chromatin immunoprecipitation
The ChIP-IT Express Sonication kit (Active Motif) was used according to the manufacturer's protocol. Cells in 150 mm dishes were formaldehyde cross-linked, harvested, and then sonicated in a Bioruptor using 10 s intervals. Chromatin was immunoprecipitated with Nfr2 (Cell Signaling #3187) or Mafk antibodies (Abcam #ab50322) and pulled down with Protein G magnetic beads (Active Motif). The DNA was reverse cross-linked and purified via the chromatin IP DNA purification kit (Active Motif). Quantitative PCR was performed using primers that flanked the AREs of HMOX1 and NQO1. Three putative AREs on the NMRAL2P locus were found by sequence analysis using the consensus sequence from Chorley et al. [40] . For the primer sequences, see Supporting Information Table 1 . expression profiles, which became even more marked after SFN treatment (Supporting Information Fig. 1A ). Approximately 50% of ß12 000 DEGs were upregulated and 50% were downregulated in HCT116 cells compared to CCD841 cells (Supporting Information Fig. 1B ). These DEGs likely reflect "cancer vs. non-cancer" differences, as well as genetic variation between the two cell lines. In HCT116 cells, 4846 genes were altered by SFN treatment (SFN effect in cancer), compared with 1691 genes in CCD841 cells ("SFN effect in non-transformed cells," Supporting Information Fig. 1B) . The distribution and fold-changes of DEGs following incubation with SFN revealed a larger spread in HCT116 cells than in CCD841 cells (Supporting Information Fig. 1C and  D) . Thus, not only were more genes altered in HCT116 cells, but the DEGs were also changed by a larger fold-difference after SFN treatment. Hierarchical clustering segregated between vehicle-and SFN-treated CCD841 and HCT116 cell lines (Fig. 1A) . KEGG analysis showed enrichment of cancer-related pathways, including upregulation of p53 signaling and downregulation of Wnt/␤-catenin signaling in SFN-treated HCT116 cells (Fig. 1B and C) . Cell cycle targets included upregulated G 2 /Mrelated genes and downregulated G 1 /S-related genes, consistent with the reported role of SFN in G 2 /M arrest [21] . As anticipated, multiple Nrf2 target genes were upregulated in HCT116 cells following SFN treatment (Supporting Information Fig. 2 ). However, among the genes most highly reversed by SFN treatment, eleven that were underexpressed in HCT116 cells compared with CCD841 cells were strongly upregulated by SFN, and 56 constitutively overexpressed genes in HCT116 cells compared with CCD841 cells were markedly downregulated by SFN (Supporting Information Fig. 3) . Notably, Loc344887 (NMRAL2P) was detected at low constitutive levels in HCT116 cells and was the most dramatically induced target of SFN (Supporting Information Fig. 3 and Fig. 1D and  E) .
Under identical SFN treatment conditions, NMRAL2P was induced more significantly in colon cancer cells than in nontransformed colonic epithelial cells (p < 0.01), namely, 1.65-fold in CCD841 cells, 7.8-fold in Caco2 cells, 12.6-fold in HT29 cells, and 35-fold in HCT116 cells (Fig. 1F) . Mining of TCGA (cancergenome.nih.gov) revealed that human colorectal cancers expressed significantly lower NMRAL2P levels than the corresponding normal tissues from patients, earmarking NMRAL2P as a potential new tumor suppressor biomarker (Fig. 1G, p < 0.001) . (D) Colony formation and (E) transwell assays with NMRAL2P knockout and vector control cells. Data for colony formation are indicative of two independent experiments, whereas three separate experiments were conducted for MTT and transwell assays. In (C-E), data = mean ± SD, n = 3; *p < 0.05, **p < 0.01, ***p < 0.001.
NMRAL2P silencing protects colon cancer cells from SFN-mediated inhibition of cell growth, colony formation, and migration
An sgRNA with complementary sequence to the NMRAL2P promoter (see NMRAL2P [upstream1], Supporting Information Table 1 ) was used to target Cas9 protein to the corresponding genomic region, seeking to disrupt transcription initiation. Screening of the genomic DNA of individual colonies, using PCR primers flanking exon 1 of NMRAL2P, identified a clone with a 390 bp deletion (Supporting Information Fig. 4 , clone 5). Sequencing confirmed that the deletion was localized to the promoter region of NMRAL2P (Fig. 2A) . The corresponding NMRAL2P knockout cells had similar overall growth and viability characteristics as the vector and mock controls (Supporting Information Fig. 5 ). No NM-RAL2P expression was detected in the knockout cells before or after SFN treatment, in contrast to the parental HCT116 line under the same experimental conditions (Fig. 2B ). In the MTT assay, NMRAL2P knockout cells were significantly less responsive than vector controls to low concentrations of SFN that attenuated cell viability (Fig. 2C) . Inhibition in the colony formation assay at 7.5 M SFN was partially rescued by NM-RAL2P silencing (Fig. 2D ), although this was not observed at 15 M SFN, a concentration known to trigger autophagy and apoptosis in HCT116 cells [21, 22] . A similar trend was noted in the transwell assay, with the inhibition of cell migration by SFN being partially rescued in NMRAL2P knockout cells incubated with 7.5 M SFN (Fig. 2E , p < 0.01).
NMRAL2P is regulated directly by Nrf2 in response to SFN treatment
In time-course experiments, NMRAL2P was upregulated within 1 h of SFN treatment and peaked at 8 h, similar to the well-known Nrf2 target gene HMOX1 and ahead of a second Nrf2-regulated gene, NQO1 (Fig. 3A) . Several SFN analogs (allyl isothiocyanate, 6-methylsulfinylhexyl isothiocyanate, 9-methylsulfinylnonyl isothiocyanate), Nrf2 activators (Oltipraz, TBHQ), and pan-HDAC inhibitors (trichostatin A, suberoylanilide hydroxamic acid, valproic acid, sodium butyrate) were compared as inducers of NMRAL2P expression. Surprisingly, pan-HDAC inhibitors either had no effect or reduced the expression of NMRAL2P at 6 and 24 h, whereas SFN analogs and Nrf2 activators induced the target gene, implicating a role for Nrf2 (Fig. 3B) . The repressive partner of Nrf2, Keap1, was knocked down via siRNA-mediated inhibition, which resulted in highly significant induction of NMRAL2P, consistent with NMRAL2P activation by Nrf2 (Fig. 3C) . In the reverse scenario, siRNAmediated knockdown of Nrf2 interfered with the ability of SFN to activate NMRAL2P (Fig. 3D) . Reduced expression of the corresponding siRNA targets, Keap1 and Nrf2, was Three putative AREs were interrogated on NMRAL2P (ARE1, ARE2, and ARE3). In panels (A-F), data = mean ± SD from two or more independent experiments; **p < 0.01, ***p < 0.001. confirmed both at the mRNA and protein level in these experiments (Fig. 3E) .
In chromatin immunoprecipitation (ChIP) assays, three putative AREs were interrogated on the NMRAL2P locus (Fig. 3F) . Upon SFN treatment, Nrf2 and its transcriptional coactivator partner, Mafk, were colocalized to ARE2, upstream of exon 2, and Mafk also interacted with ARE1, upstream of exon 1 (Fig. 3F) . Neither Nrf2 nor Mafk were detected on ARE3, upstream of exon 4. As additional controls for the ChIP assays, Nrf2 and Mafk interactions were confirmed on HMOX1 and NQO1 (Fig. 3F) . These findings supported the hypothesis that, like HMOX1 and NQO1, NMRAL2P was a direct transcriptional target of Nrf2.
NMRAL2P is a coregulator of Nrf2-dependent NQO1 induction
In subcellular fractionation experiments, NMRAL2P was readily detected in the nucleus, but not in the cytosolic compartment of vehicle-treated HCT116 cells (Fig. 4A, black bars) . After SFN treatment, there was an apparent increase in the abundance of NMRAL2P, both in the nuclear and cytosolic compartments (Fig. 4A, green bars) . Future studies should seek to corroborate these findings, for example using fluorescence in situ hybridization, but we elected to focus on the nuclear aspects related to gene regulation. From the time-course experiments (Fig. 3A) , it was postulated that early induction of NMRAL2P might serve as an upstream regulator of NQO1. To test this hypothesis, siRNAs were targeted to two different regions of the NMRAL2P transcript (siRNAs #1 and #2), which resulted in significantly reduced NMRAL2P induction following SFN treatment (Fig. 4B) . In these experiments, NQO1 mRNA and protein induction by SFN was attenuated significantly compared with the siRNA controls ( Fig. 4C and D) . Keap1 knockdown also was used to induce Nrf2; following siRNA-mediated silencing of NMRAL2P, a significant reduction was observed in the inducibility of both NMRAL2P (Fig. 4E) and NQO1 (Fig. 4F and  G) . Similar results were obtained in colon cancer cells lacking NMRAL2P expression due to CRISPR/Cas9 genome editing, with the inducibility of NQO1 being attenuated significantly after treatment with SFN (Fig. 4H) . Finally, no effect was seen on NMRAL1 after NMRAL2P knockdown or SFN Fig. 2A ). In panels (A-C), (E), (F), and (H), data = mean ± SD from two or more independent experiments; n = 3; *p < 0.05, **p < 0.01, ***p < 0.001. Information Fig. 6 ), indicating that the siRNAs and PCR primers were specific for the functional pseudogene, rather than the protein-coding gene sharing 62% homology.
treatment (Supporting
Discussion
Plasma SFN metabolites have been detected at 2 M in people consuming broccoli sprouts [43] , and chemopreventive outcomes in a mouse model of intestinal tumorigenesis were associated with tissues levels in the gastrointestinal tract of ß3-30 M total SFN [44] . Although lower SFN concentrations might be considered in future RNA-seq experiments, minimizing apoptosis endpoints [21, 22] , we sought to parallel the prior transcriptome profiling in prostate cancer cells treated with 15 M SFN, which implicated multiple cancer-related pathways [39] . In the current investigation of colon cancer cells treated with 15 M SFN, multiple cancerrelated pathways also were implicated, including cell cycle, hedgehog signaling, p53 signaling, Wnt signaling, colorectal cancer, and protein processing in ER (Fig. 1B) . Several Nrf2-dependent targets were upregulated by SFN in colon cancer cells (Supporting Information Fig. 2) . However, our attention was drawn to Loc344887 (NMRAL2P) as a transcript with low constitutive levels in colon cancer cells that was dramatically induced by SFN (Supporting Information  Fig. 3) . Importantly, this ncRNA was identified as significantly downregulated in human colorectal cancer (Fig. 1G) , suggesting a possible tumor suppressor function in the colon, and the potential to serve as a clinical biomarker in patients at risk of developing malignancy of the large intestine.
We observed that NMRAL2P, but not the protein-coding gene NMRAL1, was strongly induced by SFN in colon cancer cells, and corroborated the presence of bona fide Nrf2/Mafk binding sites in the corresponding genomic region of NM-RAL2P (Fig. 3F) . The ChIP assays focused on Nrf2 and Mafk, but we cannot rule out contributions from other MAF family members, or associated coactivators. Knockdown experiments that targeted either Keap1 or Nrf2 further supported the role of Nrf2 in regulating NMRAL2P, and loss of NM-RAL2P implicated the ncRNA as a downstream activator of NQO1. We noted, however, that NQO1 inducibility was (8 of 11) 1600769 partially retained in SFN-treated colon cancer cells even after NMRAL2P silencing via siRNA treatment or CRISPR/Cas9 genome-editing ( Fig. 4C and H) . This suggests that NM-RAL2P probably cooperates with other factors in regulating NQO1 gene activity. This is the first report to identify a functional pseudogene that is both a direct transcriptional target of Nrf2, and a downstream regulator of Nrf2-dependent NQO1 induction. Polymorphisms in NQO1 have been linked to increased risk for human colorectal cancer [45] , and an anticancer role for NQO1 also has been identified in preclinical models. For example, in a rat colon carcinogenesis model, Oltipraz treatment resulted in reduced colonic aberrant crypt foci and tumor formation associated with NQO1 induction, whereas NQO1 knockout mice were more susceptible to radiation-induced myeloproliferative disease [46] [47] [48] . Thus, a change in NQO1 activity has potential implications for cancer susceptibility in the colon and in other tissues.
It is unlikely, however, that NMRAL2P serves as a master regulator of all Nrf2-dependent target genes. This point is perhaps best exemplified by the well-known Nrf2-dependent gene HMOX1. Thus, HMOX1 was induced rapidly by SFN (Fig. 3A) , but HMOX1, like NFE2L2 (the gene coding for Nrf2), was unaffected by NMRAL2P knockdown (Supporting Information Fig. 7) . Prior reports noted that HMOX1 was upregulated at an earlier timepoint than other Nrf2-dependent target genes, including NQO1 [49, 50] , and implicated multiple factors in the dynamic regulation of HMOX1 [14, 51] . For example, Bach1 can inhibit HMOX1 induction by antagonizing Nrf2 binding [51] , whereas the SWI/SNF chromatin remodeling factor BRG1 interacts with Nrf2 to selectively induce HMOX1 [14] . TET-dependent DNA methylation changes and posttranslational modifications to Nrf2 also influence Keap1/Nrf2 interactions, and the extent of Nrf2 nuclear-cytoplasmic trafficking [17, 18, 52, 53] . These mechanisms would likely dictate the degree to which Nrf2, and perhaps Mafk, interact with NMRAL2P in the nuclear compartment.
Several colon cancer-related lncRNAs have emerged as potential prognostic biomarkers [54] [55] [56] . Mechanisms that have been implicated include lncRNA-miRNA associations, lncRNA-protein interactions, and actions as miRNA precursors or pseudogenes [57, 58] . Pseudogene PTENP1 can serve as a miRNA "decoy" for the protein-coding gene phosphatase and tensin homolog (PTEN) [59] , mutations in high-mobility group-1 pseudogenes (e.g. HMGA1P6 and HMGA1P7) alter their decoy functions that regulate HMGA1 [60] , and pseudogene MYLKP1 regulates the mRNA stability of smooth muscle myosin light-chain kinase, altering cell proliferation in cancer cells [61] . Considering the influence of SFN in regulating intracellular redox status, it is tempting to speculate on the role(s) of NMRAL2P as a functional pseudogene. One intriguing possibility centers on the emerging evidence for functional short peptides encoded by minimal open reading frames [62] . Allowing for start codons besides ATG, the NM-RAL2P transcript has several putative open reading frames for functional short peptides; one of the hypothetical candidates based on conceptual translation, hCG2041270, was listed in prior studies with TBHQ [63] . Thus, we do not formally discriminate here between possible ncRNA and/or sPEP roles of NMRAL2P. Given the diverse actions of Nrf2 in cancer etiology [10, 12, 64, 65] , we conclude that further studies are warranted on NMRAL2P/Nrf2 crosstalk and the associated direct versus indirect mechanisms of gene regulation (Fig. 5) . 
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